Developing new treatments for children with cancer presents unique challenges due to limited patient populations. Every year, over 80% of US pediatric oncology patients are treated at one of the Children’s Oncology Group’s (COG) 220+ member institutions. This enables partners to evaluate new treatments at scale through clinical trials.
Pediatric cancers are rarer than adult cancers, accounting for less than 1% of all oncological diagnoses. With such small patient populations, no single institution offers enough volume for reliable studies. COG researchers rely on coordinated, multi-institutional research to conduct trials that produce meaningful results.
The Children’s Oncology Group (COG) has a long and successful history of strategic collaboration with Industry Partners, from emerging biotech innovators to global pharmaceutical leaders. Through flexible partnership models, COG aligns scientific expertise, operational excellence, and regulatory rigor to support a wide range of industry objectives.
